Trials / Completed
CompletedNCT02224768
YERVOY® Risk Minimization Tool Effectiveness Evaluation Survey
YERVOY Risk Minimisation Tool Evaluation Survey
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 158 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the effectiveness of the YERVOY® educational Risk Minimization (RM) tools in terms of awareness about these tools, their utilization, knowledge and comprehension of Immune Related Adverse Reaction (irAR)s, and appropriate behavior by Healthcare Professional (HCP)s and patients
Detailed description
A total sample size of 160 to 200 HCPs and 160 to 200 patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ipilimumab |
Timeline
- Start date
- 2015-07-01
- Primary completion
- 2015-11-01
- Completion
- 2015-11-01
- First posted
- 2014-08-25
- Last updated
- 2015-12-21
Locations
2 sites across 2 countries: United States, United Kingdom
Source: ClinicalTrials.gov record NCT02224768. Inclusion in this directory is not an endorsement.